For adults with treatment-resistant depression, taking lamotrigine alongside intravenous ketamine or intranasal esketamine does not significantly reduce the antidepressant effect of the treatments. In a historical cohort study, response and remission rates were similar whether patients were on lamotrigine or not. There was a trend toward lower dissociation scores among those taking lamotrigine, especially with IV ketamine. The study was limited by only 13 patients on lamotrigine, so the evidence is insufficient to conclude that lamotrigine attenuates the antidepressant effect, but it may reduce dissociation.
Anxiety and depression are common in adults with chronic health conditions, harming quality of life and increasing risks. Online mind-body wellness programs—including psychology, mindful movement, breathwork, and meditation—may help, but their effectiveness across diverse chronic conditions is unclear. This pragmatic randomized controlled trial tests the online eMPower intervention at two support levels against a waitlist control. As of April 2024, 656 participants have enrolled, with 598 completing 12-week follow-up. The primary outcome compares anxiety and depression scores between the group receiving eMPower plus weekly check-ins and controls. Findings aim to clarify how people with chronic conditions engage with and benefit from online mind-body programming.